In addition, we checked for CH in the previous study from the stem cell products mobilized right before ASCT, after patients were exposed to 1–3+ lines of therapy, compared with this study which looked for CH in the PB at time of diagnosis in patients with treatment-naïve multiple myeloma. The gene discussed is C4B; the disease is AL amyloidosis.